Literature DB >> 9098308

The value of combined serum angiotensin-converting enzyme and gallium scan in diagnosing ocular sarcoidosis.

W J Power1, R A Neves, A Rodriguez, M Pedroza-Seres, C S Foster.   

Abstract

PURPOSE: To evaluate the role of combined serum angiotensin-converting enzyme (ACE) activity and whole-body gallium (67GA) scanning in diagnosing sarcoidosis in patients with features consistent with ocular sarcoidosis but with normal or equivocal chest radiographs.
METHODS: Serum ACE levels and whole-body 67GA scans were obtained as part of the initial workup in 22 patients with active ocular inflammation and ultimately biopsy-proven sarcoidosis (sarcoid uveitis group). A second group consisting of 70 patients with active uveitis in whom sarcoidosis also was considered a diagnostic possibility also was studied. All 70 patients ultimately had a definitive diagnosis other than sarcoidosis (nonsarcoid uveitis). All patients in this group also had a serum ACE and whole-body 67GA scan performed as part of their initial investigations.
RESULTS: All patients in the sarcoid uveitis group had either an elevated ACE level or an abnormal scan. In 16 of the 22 patients, results of both tests were abnormal. In no patient in the nonsarcoid uveitis group were results of both tests abnormal. The sensitivity of an elevated ACE in diagnosing sarcoidosis was 73% and the specificity was 83%. Using the combination of a positive 67GA scan and an elevated ACE, the specificity for diagnosis was 100% and the sensitivity was 73%.
CONCLUSIONS: The combination of serum ACE level and whole-body 67GA scan increases the diagnostic specificity without affecting sensitivity in patients with clinically suspicious ocular sarcoidosis who have normal or equivocal chest radiographs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9098308     DOI: 10.1016/s0161-6420(95)30763-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

Review 1.  Ocular involvement in sarcoidosis.

Authors:  A Rothova
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  Reliability of expert interpretation of retinal photographs for the diagnosis of toxoplasma retinochoroiditis.

Authors:  M R Stanford; L Gras; A Wade; R E Gilbert
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

3.  Gallium scan in diagnosing ocular sarcoidosis.

Authors:  Shatriah Ismail; Zunaina Embong; Wan Hazabbah Wan Hitam
Journal:  Malays J Med Sci       Date:  2005-01

4.  [Heerfordt's syndrome -- a rare initial manifestation of sarcoidosis].

Authors:  C Walter; A Schwarting; T Hansen; G Weibrich
Journal:  Mund Kiefer Gesichtschir       Date:  2005-01

5.  Cistoid macular edema as first manifestation of sarcoidosis.

Authors:  Lucia Cabrillo-Estevez; Lourdes de Juan-Marcos; Danai Kyriakou; Emiliano Hernández-Galilea
Journal:  Int Ophthalmol       Date:  2013-12-10       Impact factor: 2.031

6.  Approach to the diagnosis of the uveitides.

Authors:  Douglas A Jabs; Jacqueline Busingye
Journal:  Am J Ophthalmol       Date:  2013-05-10       Impact factor: 5.258

7.  The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases.

Authors:  Ozlem Sahin; Alireza Ziaei; Eda Karaismailoğlu; Nusret Taheri
Journal:  BMC Ophthalmol       Date:  2016-02-16       Impact factor: 2.209

8.  Case report: middle-aged woman from Ghana with unsteady gait and enlarging cerebellar mass.

Authors:  Bharat Bajantri; Sindhaghatta Venkatram; Masooma Niazi; Tushi Singh; Gilda Diaz-Fuentes
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

9.  Understanding and using sensitivity, specificity and predictive values.

Authors:  Rajul Parikh; Annie Mathai; Shefali Parikh; G Chandra Sekhar; Ravi Thomas
Journal:  Indian J Ophthalmol       Date:  2008 Jan-Feb       Impact factor: 1.848

10.  Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis.

Authors:  Enken Gundlach; Michael Marcus Hoffmann; Antje Prasse; Sonja Heinzelmann; Thomas Ness
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.